Microcap Ledger Xilio Therapeutics, Inc. $XLO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Fiscal year end
- December 31
- Shares outstanding
- 5,782,511 [10-K 2026-03-23]
What the company doesAI summary of filing
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies designed to selectively activate within the tumor microenvironment to treat cancer. The company uses proprietary masking technology to design biologics that remain inactive until reaching tumors, where tumor-specific proteases activate them to generate localized anti-tumor immune responses while minimizing systemic side effects. Xilio is advancing multiple wholly-owned programs (including XTX501, a bispecific PD-1/masked IL-2; masked T cell engagers targeting PSMA/STEAP1 and CLDN18.2; and efarindodekin alfa, a masked IL-12) alongside collaborative programs with AbbVie and Gilead. The company is pre-revenue and has not yet reported clinical data demonstrating product efficacy sufficient for regulatory approval. [10-K 2026-03-23]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $31.34M | −$15.90M | −$41.10M | $136.04M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $43.77M | −$35.04M | −$4.99M | $137.53M | [10-K 2026-03-23] |
| FY ended Dec 2024 | $6.34M | −$58.24M | −$18.38M | $55.29M | [10-K 2026-03-23] |
- Quarterly cash burn
- −$20.55M
- Cash runway Estimate
- ~19.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-05-10 | 36,912,373 | [10-Q 2024-05-14] |
| 2024-08-01 | 43,952,491 | [10-Q 2024-08-08] |
| 2024-11-01 | 43,958,074 | [10-Q 2024-11-07] |
| 2025-03-03 | 51,773,717 | [10-K 2025-03-11] |
| 2025-05-05 | 51,782,273 | [10-Q 2025-05-08] |
| 2025-08-08 | 51,827,910 | [10-Q 2025-08-14] |
| 2025-11-11 | 52,500,328 | [10-Q 2025-11-13] |
| 2026-03-18 | 5,782,511 | [10-K 2026-03-23] |
- Shelf registration
- S-3 filed 2026-05-12; declared effective 2026-05-29 [S-3 2026-05-12]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-10-03. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-10-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-03] |
| 2025-08-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-28] |
| 2025-04-08 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-08] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations |
| 2026-06-12 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-27 | S-3/A | Registration statement |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | S-3 | Registration statement |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations |
Alerts for $XLO
Email me when Xilio Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.